Abstract:Expression of inducible heat shock protein 70 (HSP70) in tumor cells has been proposed to enhance their immunogenicity. However, HSP70 has also been demonstrated to prevent tumor cell death, a key process for the development of tumor cell immunogenicity. In the present study, we investigated the in¯uence of the HSP70 protein level on PRO colon cancer cell growth and immunogenicity in syngeneic BDIX rats and nude mice. These cells have a basal expression of HSP70 which can be substantially increased by heat sho… Show more
“…Overexpression of HSP70 has been described in various tumors and has been found to be associated with enhanced tumorigenicity and resistance to therapy (2). In accordance with these findings, experimental down-regulation of HSP70 in tumor cells has been reported to enhance tumor regression in animal models (3)(4)(5).…”
The stress-inducible heat shock protein (HSP) 70 is known to function as an endogenous danger signal that can increase the immunogenicity of tumors and induce CTL responses. We show in this study that HSP70 also activates mouse NK cells that recognize stress-inducible NKG2D ligands on tumor cells. Tumor size and the rate of metastases derived from HSP70-overexpressing human melanoma cells were found to be reduced in T and B cell-deficient SCID mice, but not in SCID/beige mice that lack additionally functional NK cells. In the SCID mice with HSP70-overexpressing tumors, NK cells were activated so that they killed ex vivo tumor cells that expressed NKG2D ligands. In the tumors, the MHC class I chain-related (MIC) A and B molecules were found to be expressed. Interestingly, a counter selection was observed against the expression of MICA/B in HSP70-overexpressing tumors compared with control tumors in SCID, but not in SCID/beige mice, suggesting a functional relevance of MICA/B expression. The melanoma cells were found to release exosomes. HSP70-positive exosomes from the HSP70-overexpressing cells, in contrast to HSP70-negative exosomes from the control cells, were able to activate mouse NK cells in vitro to kill YAC-1 cells, which express NKG2D ligands constitutively, or the human melanoma cells, in which MICA/B expression was induced. Thus, HSP70 and inducible NKG2D ligands synergistically promote the activation of mouse NK cells resulting in a reduced tumor growth and suppression of metastatic disease.
“…Overexpression of HSP70 has been described in various tumors and has been found to be associated with enhanced tumorigenicity and resistance to therapy (2). In accordance with these findings, experimental down-regulation of HSP70 in tumor cells has been reported to enhance tumor regression in animal models (3)(4)(5).…”
The stress-inducible heat shock protein (HSP) 70 is known to function as an endogenous danger signal that can increase the immunogenicity of tumors and induce CTL responses. We show in this study that HSP70 also activates mouse NK cells that recognize stress-inducible NKG2D ligands on tumor cells. Tumor size and the rate of metastases derived from HSP70-overexpressing human melanoma cells were found to be reduced in T and B cell-deficient SCID mice, but not in SCID/beige mice that lack additionally functional NK cells. In the SCID mice with HSP70-overexpressing tumors, NK cells were activated so that they killed ex vivo tumor cells that expressed NKG2D ligands. In the tumors, the MHC class I chain-related (MIC) A and B molecules were found to be expressed. Interestingly, a counter selection was observed against the expression of MICA/B in HSP70-overexpressing tumors compared with control tumors in SCID, but not in SCID/beige mice, suggesting a functional relevance of MICA/B expression. The melanoma cells were found to release exosomes. HSP70-positive exosomes from the HSP70-overexpressing cells, in contrast to HSP70-negative exosomes from the control cells, were able to activate mouse NK cells in vitro to kill YAC-1 cells, which express NKG2D ligands constitutively, or the human melanoma cells, in which MICA/B expression was induced. Thus, HSP70 and inducible NKG2D ligands synergistically promote the activation of mouse NK cells resulting in a reduced tumor growth and suppression of metastatic disease.
“…Hsp70 is abundantly expressed in malignant tumors of various origins (for review, see Jäättelä 1999), and its expression correlates with increased cell proliferation, poor differentiation, lymph node metastases, and poor therapeutic outcome in human breast cancer (Ciocca et al 1993;Lazaris et al 1997;Vargas-Roig et al 1997. Furthermore, numerous experimental cancer models have demonstrated the tumorigenic potential of Hsp70 in rodents (Jäättelä 1995;Seo et al 1996;Volloch and Sherman 1999;Gurbuxani et al 2001). In support of the hypothesis that Hsp70 promotes tumorigenesis via its pro-survival function, it can effectively inhibit cell death induced by a wide range of stimuli including several cancer-related stresses like hypoxia, inflammatory cytokines, monocytes, irradiation, oxidative stress, and anticancer drugs (Jäättelä et al 1992(Jäättelä et al , 1998Jäättelä and Wissing 1993;Simon et al 1995;Mosser et al 1997;Buzzard et al 1998;Vayssier et al 1998;Nylandsted et al 2004).…”
[Keywords: Heat-shock proteins 70; macrophage inhibitory cytokine-1; neoplasms; senescence; RNA interference; microarray] Supplemental material is available at http://www.genesdev.org.
“…Clinical trials using a specific inhibitor of HSP90, 17-allylamino-17-demethoxygelda- namycin, are currently being performed with encouraging results (Munster et al, 2001). We and others have recently shown that downregulation of HSP70 with antisense constructs sensitizes to apoptosis induction and even can induce spontaneous cell death (Nylandsted et al, 2000;Gurbuxani et al, 2001). At least part of the cytoprotective action of HSP70 is mediated by its interaction with AIF, which does not depend on its chaperone activity.…”
Section: Discussionmentioning
confidence: 99%
“…HSP70 overexpression has been shown to increase the tumorigenicity of cancer cells in rodent models (Jaattela, 1995). Conversely, HSP70 downregulation is sufficient to kill tumour cells or to facilitate the induction of apoptosis (Nylandsted et al, 2000;Gurbuxani et al, 2001). The antiapoptotic function of HSP70 involves interactions with several components of the apoptotic machinery.…”
Heat shock protein 70 (HSP70) can inhibit apoptosis by neutralizing and interacting with apoptosis-inducing factor (AIF), a mitochondrial flavoprotein that translocates upon apoptosis induction to the nucleus, via the cytosol. Here, we show that only members of the HSP70 family interact with AIF. Systematic deletion mapping revealed the existence of three distinct functional regions in the AIF protein: (1) a region between amino acids 150 and 228 that binds HSP70, (2) a domain between residues 367 and 459 that includes a nuclear localization sequence (NLS) and (3) a C-terminal domain beyond residue 567 required for its chromatin-condensing activity. Deletion of the 150-268 domain completely abolished HSP70 binding and facilitated the nuclear import of AIF, resulting in a gain-of-function phenotype with enhanced AIF-mediated chromatin condensation as compared to wild-type AIF. This gain-of-function phenotype was observed in wild-type control cells (which express low but significant levels of HSP70), yet was lost when AIFD150-268 was introduced into HSP70 knockout cells, underscoring the functional importance of the AIF-HSP70 interaction. Altogether, our data demonstrate that AIF inhibition by HSP70 involves cytosolic retention of AIF. Moreover, it appears that endogenous HSP70 protein levels are sufficiently elevated to modulate the lethal action of AIF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.